Trial Profile
A Phase I, Open-Label, Randomized, Two Period Crossover Study to Investigate the Effects of GW679769 on the Pharmacokinetics of Docetaxel in Subjects With Cancer.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Sep 2023
Price :
$35
*
At a glance
- Drugs Casopitant (Primary) ; Docetaxel
- Indications Chemotherapy-induced nausea and vomiting; Solid tumours
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline; GSK
- 12 Aug 2011 Additional trial investigator (Cheri Hudson) identified as reported by ClinicalTrials.gov.
- 01 Apr 2011 Results published in Cancer Chemotherapy and Pharmacology.
- 20 May 2009 Actual end date (Jul 2008) added as reported by ClinicalTrials.gov.